RxDoctor Payments Data

Daruka Mahadevan, MD

Medical Oncology · San Antonio, TXNPI 1841398302

Payments from drug & device makers

$3,113,754in general payments, 2019–2025

Across 617 payments — averaging $5046.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1M
  • Pfizer$641K
  • Merck$581K
  • Beigene, Ltd.$432K
  • Genentech, Inc.$232K
  • Seagen Inc.$70K
  • plus $123K from 24 others
$152in research payments, 2019–2025

Across 2 payments — averaging $75.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$92
  • AbbVie$60

What the payments were for

  • Consulting fees$15,19080%
  • Speaking & faculty fees$5303%
  • Travel & lodging$8775%
  • Food & beverage$2,16011%
  • Education$2141%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,113,754 in reported general payments places this provider in the 80th percentile of 495 medical oncology providers in Texas.

See all medical oncology providers in Texas

Medicare billing

Part B allowed, 2024
$72,566
Medicare patients
86
Services billed
3,259

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CabometyxCabozantinib S-Malate12$272,099
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen23$931
Prochlorperazine Maleate18$373
Levothyroxine Sodium69$319
Potassium Chloride35$236
Ondansetron OdtOndansetron12$229
Acetaminophen-CodeineAcetaminophen With Codeine11$137
Ondansetron Hcl15$119
Gabapentin22$56
Lorazepam16$46
Prednisone15$38

Paid to pharmacies, not to this prescriber.

Other medical oncology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →